Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nurix Therapeutics, Inc. - Common stock (NQ:NRIX)

9.910 +0.790 (+8.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nurix Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 Next >
Analyst Ratings for Nurix Therapeutics
 
Via Benzinga
Nurix Therapeutics's Return On Capital Employed Insights
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Analyst Ratings for Nurix Therapeutics
 
Via Benzinga
JPMorgan, Citigroup, QuidelOrtho And Other Big Stocks Moving Higher On Friday
U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Nurix Therapeutics Inc. (NASDAQ: NRIX) Highlighted for Surprising Price Action
Via Investor Brand Network
Expert Ratings for Nurix Therapeutics
 
Via Benzinga
Gilead Exercises First License Option Under Agreement With Nurix Therapeutics
 
Via Benzinga
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
From Gilead Sciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
 
Via Benzinga
Analyst Ratings for Nurix Therapeutics
 
Via Benzinga
Nurix Therapeutics's Return On Capital Employed Overview
 
Via Benzinga
Where Nurix Therapeutics Stands With Analysts
Within the last quarter, Nurix Therapeutics (NASDAQ:NRIX) has observed the following analyst ratings: 
Via Benzinga
Analyst Ratings for Nurix Therapeutics
Within the last quarter, Nurix Therapeutics (NASDAQ:NRIX) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
 
Via Benzinga
The Top 5 Stocks Cathie Wood Bought and Sold This Week
Cathie Wood's flagship ETF, the ARK Innovation ETF, hit a five-year and 52-week low this week, casting doubts on the investment manager. 
Via InvestorPlace
CSX, Veris Residential And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Cathie Wood Loads Up Over $6.7M In Adobe Stock As It Tumbles 27% In A Month — Also Adds Stake In This Biopharma Company
Cathie Wood-led ARK Investment Management bought over 23,000 shares of software maker Adobe Inc (NASDAQ: ADBE) through the 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
Why SOBR Safe Shares Surged Around 233%; Here Are 68 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Top Russell 2000 Stocks: Trading Opportunities For Next Week - Sunday, Sept. 11
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Here is a closer look at some Russell 2000 stock... 
Via Talk Markets
Tesla, Twitter And 76 Biggest Movers From Friday
Gainers Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board... 
Via Benzinga
Why Nurix Therapeutics Shares Are Rising Today
Nurix Therapeutics Inc (NASDAQ: NRIX) shares are trading higher by 13.25% to $17.52 Friday afternoon after the company announced a registered direct offering for total gross proceeds of approximately... 
Via Benzinga
Nurix Therapeutics's Return On Capital Employed Insights
Benzinga Pro data, Nurix Therapeutics (NASDAQ:NRIX) reported Q2 sales of $11.43 million. Earnings fell to a loss of $45.40 million, resulting in a 6.74% decrease from last quarter. 
Via Benzinga
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
40 Stocks Moving In Friday's Mid-Day Session
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share. 
Via Benzinga
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2022
Upgrades 
Via Benzinga
10 Biggest Price Target Changes For Friday
Keybanc boosted Broadcom Inc. (NASDAQ: AVGO) price target from $720 to $780. Broadcom shares rose 0.1% to $551.44 in pre-market trading. 
Via Benzinga
88 Biggest Movers From Yesterday
Gainers Creatd, Inc. (NASDAQ: CRTD) shares jumped 58.5% to close at $1.28 on Thursday. Creatd’s board approved a rights offering of up to $40 million for 20 million shares at $2 per unit. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.